The estimated Net Worth of Carlos Campoy is at least $59.1 ezer dollars as of 16 March 2023. Mr. Campoy owns over 1,748 units of CytomX Therapeutics Inc stock worth over $50,073 and over the last 6 years he sold CTMX stock worth over $9,069. In addition, he makes $0 as Chief Financial Officer és Senior Vice President at CytomX Therapeutics Inc.
Carlos has made over 2 trades of the CytomX Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,748 units of CTMX stock worth $3,461 on 16 March 2023.
The largest trade he's ever made was selling 3,949 units of CytomX Therapeutics Inc stock on 19 July 2022 worth over $5,608. On average, Carlos trades about 475 units every 20 days since 2018. As of 16 March 2023 he still owns at least 38,224 units of CytomX Therapeutics Inc stock.
You can see the complete history of Mr. Campoy stock trades at the bottom of the page.
Carlos Campoy serves as Chief Financial Officer, Senior Vice President of the Company. Mr. Campoy brings over 30 years of financial and leadership experience, the majority from publicly held companies within the healthcare and biopharmaceutical sectors. Prior to joining CytomX, Mr. Campoy held the position of chief financial officer at Alder BioPharmaceuticals, Inc., a public biopharmaceutical company acquired in October 2019 by Lundbeck A/S, from December 2018 to November 2019. During his time at Alder, Mr. Campoy led the finance organization and readied the company for commercial launch of its lead program, eptinezumab. Prior to Alder, Mr. Campoy was a partner at Think Forwards, a boutique financial consulting firm, from September 2017 to December 2018. Prior to his position at Think Forwards, Mr. Campoy held the role of vice president of finance at Allergan plc from July 2014 to November 2016. Prior to joining Allergan, Mr. Campoy held senior financial leadership positions at Eli Lilly and Company from 1996 to 2014, including most recently as chief financial officer of Eli Lilly Japan K.K. Mr. Campoy holds a Certified Management Accountant (CMA) designation. Mr. Campoy received his M.B.A. in Finance and Decision Information Systems from Indiana University and his B.S. in Management from Faculdade C.C. Administracao de Tupa, in São Paulo, Brazil.
Carlos Campoy is 55, he's been the Chief Financial Officer és Senior Vice President of CytomX Therapeutics Inc since 2020. There are 10 older and 8 younger executives at CytomX Therapeutics Inc. The oldest executive at CytomX Therapeutics Inc is Frederick W. Gluck, 86, who is the Co-Founder & Independent Director.
Carlos's mailing address filed with the SEC is C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709.
Over the last 10 years, insiders at CytomX Therapeutics Inc have traded over $57,157,858 worth of CytomX Therapeutics Inc stock and bought 662,000 units worth $7,876,720 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Harbor Master Investors (Ca... és James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $48,707. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth $14,738.
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include: